Spots Global Cancer Trial Database for A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Official Title: Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse
Study ID: NCT00546780
Conditions
Study Description
Brief Summary: This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
Detailed Description: Phase 3 combination study comparing tanespimycin (KOS-953) plus bortezomib to bortezomib alone in patients with multiple myeloma in first relapse after failure of previous anti-cancer therapy and/or bone marrow transplantation. Primary objective is to compare the progression-free survival (PFS) associated with the use of tanespimycin (KOS-953) in combination with bortezomib versus that associated with administration of bortezomib alone.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
Moores Ucsd Cancer Center, La Jolla, California, United States
University Of California Medical Center, San Francisco, California, United States
Rocky Mountain Cancer Centers, Denver, Colorado, United States
University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
University Of Kansas Medical Center, Westwood, Kansas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Health System Irb, Detroit, Michigan, United States
Capitol Comprehensive Cancer Care Center, Jefferson City, Missouri, United States
Columbia University Medical Center (Cumc), New York, New York, United States
Wake Forest Univ Health Sciences, Winston-Salem, North Carolina, United States
Kaiser Permanente Oncology/Hematology, Portland, Oregon, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Baylor University Medical Center, Dallas, Texas, United States
University Of Virginia Health System, Charlottesville, Virginia, United States
Medical College Of Wisconsin, Milwaukee, Wisconsin, United States
Local Institution, Edmonton, Alberta, Canada
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
